Baicalein-phospholipid complex: A novel drug delivery technology for phytotherapeutics

Current Drug Discovery Technologies

Volumn 10, Issue 3, 2013, Pages 224-232

  Rawat, Devendra Singh ^a   Thakur, Bandana K ^a   Semalty, Mona ^a   Semalty, Ajay ^a   Badoni, Prabhakar ^a   Rawat, Mohan Singh Maniyari ^a  

^a H N B GARHWAL UNIVERSITY   (India)

Author keywords

Baicalein; Differential scanning calorimetry; FT IR; Phosphatidylcholine; Scanning electron microscopy; Solubility behavior and controlled release; X RPD

Indexed keywords

BAICALEIN; OCTANOL; PHOSPHOLIPID;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL INTERACTION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; INFRARED RADIATION; MORPHOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THERMAL ANALYSIS; X RAY DIFFRACTION; X RAY POWDER DIFFRACTOMETRY;

CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; FLAVANONES; MICROSCOPY, ELECTRON, SCANNING; PHOSPHOLIPIDS; PHYTOTHERAPY; POWDER DIFFRACTION; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; X-RAY DIFFRACTION;

EID: 84882355247     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811310030005     Document Type: Article

References (39)

1. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 545-53.
2. Franceschi F, Giori A. Phospholipid complexes of olive fruits or leaves extracts having improved bioavailability. World Patent 2007118631, 2007.
3. Huang WH, Lee AR, Yang CH. Antioxidative and antiinflammatory activity of polyhydroxy flavonoids. Bioscienca Biochem Technol 2006; 70(10): 2371-80.
4. Nijlen TV, Brennan K, Mooter V, Blaton N, Kinget R, Augustijns P. Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm 2003; 254: 173-81.
5. Nokhodchi A. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci 2005; 8: 18-25.
6. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MSM. Pharmacosomes: the lipid based novel drug delivery system. Expert Opin Drug Deliv 2009; 6(6): 599-612.
7. Semalty A, Semalty M, Rawat MSM, Federico F. Supramolecular phospholipids-polyphenolic interactions: the PHYTOSOME® strategy to improve the bioavailability of phytochemicals. Fitoterapia 2010; 81: 306-14.
8. Ciesielska E, Wolszczak M, Gulanowski B, Szulawska A, Kochman A, Metodiewa D. In vitro antileukemic, antioxidant and prooxidant activities of antoksyd S (C/E/XXI): a comparison with baicalin and baicalein. in vivo 2004; 8: 497-504.
9. Wang X, Li X, Li H. Reassessment of anti oxidant activity of baicalein in vitro. Asian J Pharm Biol Res 2011; 1(2): 186-94.
10. Kang K, Fong WP, Tsang PWK. Antifungal activity of baicalein against candidakrusei does not involve apoptosis. Mycopathologia 2010; 170(6): 391-39.
11. Huang Y, Tsang SY, Yao X, Chen ZY. Biological properties of baicalein in cardiovascular system. Curr Drug Targets 2004; 5(2): 177-84.
12. Woo AYH, Cheng CHK, Waye MMY. Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 2005; 65(1): 244-53.
13. Zhao J, Zhang ZP, Chen HS, Chen XH, Zhang XQ. Preparation and anti-HIV activity study of baicalien and its benzylated derivative. Yao Xue Xue Bao 1997; 32(2): 140-3.
14. Zhang DY, Wu J, Ye F, et al. Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Research 2003; 63(14): 4037-43.
15. Peng Y, Li Q, Li Kun, Zhao H, Han Z, Li F, Sun M, Zhang Y. Antitumor activity of baicalein on the mice bearing U14 cervical cancer. African Journal of Biotechnology 2011; 10(64): 14169-76.
16. Weber ML. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituent's wogonin, baicalein and baicalin. Cancer Treat Rev 2009; 35(1): 57-68.
17. Caoa YY, Daib BD, Wanga Y, et al. In vitro activity of baicalein against candida albicans biofilms. Int J Antimicrob Agents 2008; 32(1): 73-7.
18. Nagai H, Osuga K, Koda A. Inhibition of hypersensitivity reactions by soluble derivatives of baicalein. Jpn J Pharmacol 1975; 25(6): 763-72.
19. Huanga Y, Wonga CM, Laua CW, et al. Inhibition of nitric oxide/cyclic GMP-mediated relaxation by purified flavonoids, baicalin and baicalein, in rat aortic rings. Biochem Pharmacol 2004; 67(4): 787-94.
20. Kaneko T, Chiba H, Horie N, et al. Inhibition of prostaglandin E2 production by flavone and its related compounds. in vivo 2010; 24: 55-58.
21. Lee HJ, Noh YH, Lee DY, et al. Baicalein attenuates 6-hydroxydopamine- induced neurotoxicity in SH-SY5Y cells. Eur J Cell Biol 2005; 84(11): 897-905.
22. Mu X, He G, Cheng Y, Li X, Xu B, Du G. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav 2009; 92(4): 642-8.
23. Liu TM, Jiang XH. Studies on the absorption kinetics of baicalin and baicalein in rats' stomachs and intestines. Zhongguo Zhong Yao Za Zhi 2006; 31(12): 999-1001.
24. Liu TM, Jiang XH Zhang MJ, Liao SJ, Chen Z. Absorption characteristics of baicalin and baicalein in rat small intestine. Chinese Pharmaceutical Journal 2006; 41(23): 1784-7.
25. Xing J, Chen XY, Zhong DF. Absorption, excretion and enterohepatic circulation of baicalein in Rats. Asian Journal of Pharmacodynamics and Pharmacokinetics 2006; 6(1): 29-37.
26. Zhang L, Zhang J, Wang L, Xia H. Ocular pharmacokinetics and availability of topically applied baicalein in rabbits. Curr Eye Res 2009; 34(4): 257-63.
27. Zhang L, Lin G, Chang Q, Zuo Z. Role of intestinal first-pass metabolism of baicalein in its absorption process. Pharm Res 2005; 22(7): 1050-8.
28. Lai MY, Hsiu SL, Chen CC, Hou YC, Chao PD. Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae radix in humans. Biol Pharm Bull 2003; 26 (1): 79-83.
29. Lai MY, Hou YC, Hsiu SL, Chen CC, Chao PDL. Relative flavone bioavailability of Scutellariae radix between traditional decoction and commercial powder preparation in humans. Journal of Food and Drug Analysis 2002; 10(2): 75-80.
30. Singh D, Rawat MSM, Semalty A, Semalty M. Gallic acidphospholipid complex: drug incorporation and physicochemical characterization. Lett Drug Des Discov 2011; 8: 284-91.
31. Li Y, Yang DJ, Chen SL, Chen SB, Chan ASC. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Pharm Res 2007; 25: 563-77.
32. Semalty A, Semalty M, Singh D, Rawat MSM. Preparation and characterization of phospholipid complexes of naringenin for effective drug delivery. J Incl Phenom Mac Chem 2010; 67: 253-60.
33. Babu GVMM, Prasad CDS, Murthy KVR. Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly watersoluble drug nimodipine. Int J Pharm 2002; 234: 1-17.
34. Moneghini M, Kikie I, Voinovich D, Perissutti B, Grcic JF. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization and in vitro dissolution. Int J Pharm 2001; 222: 129-38.
35. Liu J, Qiu L, Gao J, Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-betacyclodextrin. Int J Pharm 2006; 312(1-2): 137-43.
36. Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm 2006; 307: 77-82.
37. Lichtenberger LM, Wang ZM, Romero JJ, et al. Non steroidal antiinflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAIDinduced gastrointestinal injury. Nature Med 1995; 11: 154-8.
38. Lichtenberger LM, Ulloa C, Vanous AL, et al. Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther 1996; 277: 1221-7.
39. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes. part I. micronization of neat particles. Int J Pharm 2005; 288: 3-10.